Visgeneer (4197) - Total Assets
Based on the latest financial reports, Visgeneer (4197) holds total assets worth NT$335.03 Million TWD (≈ $10.56 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Visgeneer debt service capacity to assess how comfortably operating cash covers total debt obligations.
Visgeneer - Total Assets Trend (2011–2025)
This chart illustrates how Visgeneer's total assets have evolved over time, based on quarterly financial data. See Visgeneer book value and equity for net asset value and shareholders' equity analysis.
Visgeneer - Asset Composition Analysis
Current Asset Composition (December 2025)
Visgeneer's total assets of NT$335.03 Million consist of 44.6% current assets and 55.4% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 20.7% |
| Accounts Receivable | NT$22.93 Million | 6.8% |
| Inventory | NT$50.85 Million | 15.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Visgeneer's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Visgeneer (4197) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Visgeneer's current assets represent 44.6% of total assets in 2025, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 20.7% of total assets in 2025, down from 28.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 6.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 15.2% of total assets.
Visgeneer Competitors by Total Assets
Key competitors of Visgeneer based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Visgeneer - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.69 | 4.21 | 3.01 |
| Quick Ratio | 2.43 | 2.73 | 2.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$108.86 Million | NT$106.75 Million | NT$145.43 Million |
Visgeneer - Advanced Valuation Insights
This section examines the relationship between Visgeneer's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.35 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 0.9% |
| Total Assets | NT$335.03 Million |
| Market Capitalization | $8.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Visgeneer's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Visgeneer's assets grew by 0.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Visgeneer (2011–2025)
The table below shows the annual total assets of Visgeneer from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$335.03 Million ≈ $10.56 Million |
+0.89% |
| 2024-12-31 | NT$332.09 Million ≈ $10.46 Million |
-16.39% |
| 2023-12-31 | NT$397.18 Million ≈ $12.51 Million |
-18.40% |
| 2022-12-31 | NT$486.74 Million ≈ $15.33 Million |
+13.98% |
| 2021-12-31 | NT$427.04 Million ≈ $13.45 Million |
-7.56% |
| 2020-12-31 | NT$461.96 Million ≈ $14.55 Million |
-3.91% |
| 2019-12-31 | NT$480.76 Million ≈ $15.15 Million |
+6.54% |
| 2018-12-31 | NT$451.24 Million ≈ $14.22 Million |
-17.60% |
| 2017-12-31 | NT$547.64 Million ≈ $17.25 Million |
+5.43% |
| 2016-12-31 | NT$519.45 Million ≈ $16.37 Million |
-3.69% |
| 2015-12-31 | NT$539.33 Million ≈ $16.99 Million |
+42.14% |
| 2014-12-31 | NT$379.44 Million ≈ $11.95 Million |
+14.16% |
| 2013-12-31 | NT$332.39 Million ≈ $10.47 Million |
+17.66% |
| 2012-12-31 | NT$282.50 Million ≈ $8.90 Million |
+25.62% |
| 2011-12-31 | NT$224.87 Million ≈ $7.08 Million |
-- |
About Visgeneer
Visgeneer Inc. provides health solutions in the fields of medical device, cosmetics and skin care, Zeaxanthin, and cancer gene diagnostics in Europe and Asia. The company offers blood glucose and ketone, uric acid, and cholesterol monitoring systems. It also provides functional masks, such as wood pulp mask, invisible mask, black mask, pure cloth mask, and bio cellulose mask; face cream, night cr… Read more